An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the direct costs associated with switching, in
either direction, between a rapid-acting analog therapy and short-acting human insulin
therapy within the first year following the switch. The additional goals are: 1)to assess the
impact of a switch from or to a rapid-acting analog insulin therapy on patient treatment
satisfaction, 2) to assess the impact of a switch from or to a rapid-acting analog insulin
therapy on patient quality of life, 3) to assess the impact of switch from or to the
rapid-acting analog insulin therapy on the quality of metabolic control and, 4) to estimate
the total costs (direct and indirect) associated with switching, in either direction between
rapid-acting analog and short-acting human insulin within the first year following the
switch.